BR0009868A - Usos de um inibidor da sìntese de glicosilceramida para a fabricação de um medicamento, de n-butildeoxinojirimicina, e de um agente capaz de aumentar a taxa de degradação de glicolipìdeo neuronal, e, produto - Google Patents

Usos de um inibidor da sìntese de glicosilceramida para a fabricação de um medicamento, de n-butildeoxinojirimicina, e de um agente capaz de aumentar a taxa de degradação de glicolipìdeo neuronal, e, produto

Info

Publication number
BR0009868A
BR0009868A BR0009868-0A BR0009868A BR0009868A BR 0009868 A BR0009868 A BR 0009868A BR 0009868 A BR0009868 A BR 0009868A BR 0009868 A BR0009868 A BR 0009868A
Authority
BR
Brazil
Prior art keywords
product
manufacture
rate
butildeoxinojirimicina
drug
Prior art date
Application number
BR0009868-0A
Other languages
English (en)
Inventor
Steven Walkley
Gordon D Holt
Original Assignee
Oxford Glycosciences Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd filed Critical Oxford Glycosciences Uk Ltd
Publication of BR0009868A publication Critical patent/BR0009868A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"USOS DE UM INIBIDOR DA SìNTESE DE GLICOSIL CERAMIDA PARA A FABRICAçãO DE UM MEDICAMENTO, DE N-BUTILDEOXINOJIRIMICINA, E DE UM AGENTE CAPAZ DE AUMENTAR A TAXA DE DEGRADAçãO DE GLICOLIPìDEO NEURONAL, E, PRODUTO". A presente invenção diz respeito ao tratamento de condições tais como a doença de armazenamento C de Niemann-Pick, a doença de Alzheimer , a epilepsia, acidente vascular cerebral e doença de Parkinson, e, em particular, ao uso de inibidores da sintese de glicosilceramida em tal tratamento. Inibidores preferidos da síntese de glicosilcera-inida são os iminoaçúcares estruturados, e incluem N-butildeoxinojirimicina (NB-DNJ), N-butildeoxigalactonojirimicina (NB-DGJ) e N-nonildeoxinojirimicina (NNDNJ).
BR0009868-0A 1999-04-20 2000-04-20 Usos de um inibidor da sìntese de glicosilceramida para a fabricação de um medicamento, de n-butildeoxinojirimicina, e de um agente capaz de aumentar a taxa de degradação de glicolipìdeo neuronal, e, produto BR0009868A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9909064.9A GB9909064D0 (en) 1999-04-20 1999-04-20 Therapies
PCT/GB2000/001563 WO2000062780A1 (en) 1999-04-20 2000-04-20 Use of glucosylceramide synthesis inhibitors in therapy

Publications (1)

Publication Number Publication Date
BR0009868A true BR0009868A (pt) 2002-01-08

Family

ID=10851915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009868-0A BR0009868A (pt) 1999-04-20 2000-04-20 Usos de um inibidor da sìntese de glicosilceramida para a fabricação de um medicamento, de n-butildeoxinojirimicina, e de um agente capaz de aumentar a taxa de degradação de glicolipìdeo neuronal, e, produto

Country Status (12)

Country Link
US (1) US6683076B2 (pt)
EP (1) EP1171129A1 (pt)
JP (1) JP2002542195A (pt)
AU (1) AU776947B2 (pt)
BR (1) BR0009868A (pt)
CA (1) CA2368814C (pt)
GB (1) GB9909064D0 (pt)
IL (2) IL145907A0 (pt)
MX (1) MXPA01010706A (pt)
NO (1) NO20015112L (pt)
WO (1) WO2000062780A1 (pt)
ZA (1) ZA200108413B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
WO2000066105A2 (en) * 1999-04-30 2000-11-09 The Trustees Of Boston College Treatment of epilepsy with imino sugars
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
JP4575156B2 (ja) * 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
WO2004007454A1 (en) 2002-07-17 2004-01-22 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
MXPA05002292A (es) * 2002-08-27 2006-05-22 Nestle Sa Prevencion de tratamiento de tejido epitelial o perdida de pelo.
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
US20060025449A1 (en) * 2004-03-25 2006-02-02 United Therapeutics Use of N-substituted imino sugars for appetite suppression
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US7884115B2 (en) * 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
JP5431961B2 (ja) * 2007-01-05 2014-03-05 マウント シナイ スクール オブ メディシン 酸性セラミダーゼおよび細胞の生存を促進する方法
WO2008109610A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008109287A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US20100105687A1 (en) * 2007-03-06 2010-04-29 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CN105879047A (zh) 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
PL2753346T3 (pl) 2011-09-07 2020-10-19 Mount Sinai School Of Medicine Ceramidaza i różnicowanie komórek
WO2013181530A1 (en) 2012-06-01 2013-12-05 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
MX2015012471A (es) 2013-03-14 2016-08-03 Icahn School Med Mount Sinai Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
NL2021840B1 (en) 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
US20230140216A1 (en) 2020-02-03 2023-05-04 Gain Therapeutics Sa Combination therapy for treating mps1
IT202000008917A1 (it) 2020-04-24 2021-10-24 Biovalley Invest Partner S R L Composizioni antivirali

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
EP0912179B1 (en) * 1996-07-15 2006-04-12 MacroZyme DNM B.V. Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
AU8286998A (en) * 1997-07-03 1999-01-25 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Genes for niemann-pick type c disease
US6610703B1 (en) * 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
CA2378776A1 (en) * 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases

Also Published As

Publication number Publication date
AU776947B2 (en) 2004-09-30
IL145907A (en) 2011-05-31
GB9909064D0 (en) 1999-06-16
MXPA01010706A (es) 2002-08-20
AU4133300A (en) 2000-11-02
US20020115667A1 (en) 2002-08-22
US6683076B2 (en) 2004-01-27
CA2368814A1 (en) 2000-10-26
NO20015112L (no) 2001-12-10
CA2368814C (en) 2010-09-07
NO20015112D0 (no) 2001-10-19
WO2000062780A1 (en) 2000-10-26
JP2002542195A (ja) 2002-12-10
EP1171129A1 (en) 2002-01-16
ZA200108413B (en) 2003-03-26
IL145907A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
BR0009868A (pt) Usos de um inibidor da sìntese de glicosilceramida para a fabricação de um medicamento, de n-butildeoxinojirimicina, e de um agente capaz de aumentar a taxa de degradação de glicolipìdeo neuronal, e, produto
BR0009913A (pt) Uso de um inibidor da sìntese de glicolipìdeos e um agente capaz de aumentar a taxa de degradação de glicolipìdeos, produto, e, composição farmacêutica
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
TR200201067T2 (tr) Bir tramadol maddesi ve bir antikonvülsan ilaç içeren bileşimler
HK1042655A1 (en) Use of erythropoietin in the production of the drugs for the treatment of cerebral ischaemia.
WO2018222954A1 (en) Methods and compositions for treating excessive sleepiness
EP2108390A3 (en) Device for local and/or regional delivery employing liquid formulations of therapeutic agents
ES2330291A1 (es) Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
CA2984088A1 (en) Combinations of cannabinoids and n-acylethanolamines
PE20020694A1 (es) Composiciones orales que tienen caracteristicas esteticas del consumidor mejoradas
ES2143157T3 (es) Composicion estable que contiene acido ascorbico.
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
HK1048764A1 (en) Oligosaccaride aldonic acids and their topical use
PL1962815T3 (pl) Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne
EP1234568A4 (en) COSMETIC PRODUCTS
BR0211063A (pt) Sais de derivados anticonvulsivantes
ES2126368T3 (es) Composicion estable que contiene un enzima.
BR0211936A (pt) Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos
FI962550A (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
ATE314397T1 (de) Eine mischung von nicht-sulfatierten oligosacchariden auf der basis von fukose, eine diese mischung enthaltende, kosmetische oder pharmazeutische zusammensetzung und deren verwendungen in der kosmetik und pharmazie
HK1037135A1 (en) Non therapeutic use of n-acetylglucosamine as skin exfoliant
CN113766913A (zh) 短时间溶解微针
MY140104A (en) Silk soap comprising sericin protein
CA2641571A1 (en) Treatment of osteoarthritis
ES2718848T3 (es) Composición tópica filmógena y su uso para tratar o prevenir la onicofagia

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ACTELION PHARMACEUTICALS LIMITED (CH)

Free format text: TRANSFERIDO DE: OXFORD GLYCOSCIENCES (UK) LIMITED

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.